These findings highlight sPD-L1’s broader applicability across cancers, making it valuable for diagnostics and treatment monitoring, due to its direct involvement in immune suppression [33], correlation with tumor burden, aggressiveness [34] and consistent association with clinical outcomes [8,35,36]. Here, SPDL1 is linked to neoplasm.